Cardiovascular & Precision Oncology Applications
In 2026, contrast media is increasingly used for Theranostics (therapy + diagnostics) in South Korea’s specialized cancer and heart centers.
Photon-Counting CT (PCCT): Several top-tier Korean hospitals have installed the latest PCCT scanners. These require specific "K-edge" contrast agents that allow for "Multi-Energy" imaging—literally color-coding different tissues (e.g., distinguishing between calcium, iodine, and soft plaque in an artery).
Organ-Specific Agents: 2026 has seen the rollout of tissue-specific contrast agents, such as liver-specific gadoxetic acid, which allows for the detection of tiny metastatic lesions ($<5\text{ mm}$) that were previously invisible on standard scans.
Molecular Imaging: Researchers at institutions like KAIST are developing "Stimuli-Responsive" contrast agents that only "turn on" their signal when they encounter specific pH levels or enzymes associated with aggressive tumor growth.

